1887

Abstract

In a recent study, we described a group of monoclonal antibodies that identify five high molecular mass proteins which associate with intermediate filaments in the cytoplasm and accumulate in nuclear foci as well. The proteins have been designated pNDCFs, proteins associated with nuclear dots and cytoplasmic filaments. Their expression in human B cells was upregulated by Epstein-Barr virus (EBV) infection or by exposure to anti-CD40 antibodies and IL4. Phenotypically representative (type I) Burkitt’s lymphoma (BL) cell lines do not express pNDCFs or, if they do, the proteins accumulate preferentially in nuclear dots. Type III BL cell lines that have drifted to a more immunoblastic phenotype during passage and EBV-transformed lymphoblastoid cell lines (LCLs) of non-neoplastic origin express these proteins regularly at high levels. They are preferentially but not exclusively associated with vimentin filaments in the cytoplasm. Here we show that all five pNDCFs can be up- regulated by expressing the EBV-encoded membrane protein LMP1 in type I BLs. Three of them could also be upregulated in the human keratino- cyte cell line RHEK-1 by LMP1 transfection. This upregulation was paralleled by the LMP1-induced increase in vimentin expression in both cell types. One of the pNDCFs, detected by the MAb DM_4A6, accumulated in cap-like structures under the cell membrane that colocalized with membrane patches of LMP1, in addition to its localization in nuclear dots and in association with cytoplasmic vimentin filaments.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/0022-1317-78-8-2031
1997-08-01
2022-05-28
Loading full text...

Full text loading...

/deliver/fulltext/jgv/78/8/9267004.html?itemId=/content/journal/jgv/10.1099/0022-1317-78-8-2031&mimeType=html&fmt=ahah

References

  1. Abbot S. D., Rowe M., Cadwallader K., Ricksten A., Gordon J., Wang F., Rymo L., Rickinson A. B. 1990; Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. Journal of Virology 64:2126–2134
    [Google Scholar]
  2. Alfieri C., Birkenbach M., Kieff E. 1991; Early events in Epstein-Barr virus infection of human B lymphocytes [published erratum appears in Virology 1991; 185(2), 946]. Virology 181:595–608
    [Google Scholar]
  3. Allday M. J., Crawford D. H., Griffin B. E. 1989; Epstein-Barr virus latent gene expression during the initiation of B cell immortalization. Journal of General Virology 70:1755–1764
    [Google Scholar]
  4. Ben-Bassat H., Goldblum N., Mitrani S., Goldblum T., Yoffey J. M., Cohen M. M., Bentwich Z., Ramot B., Klein E., Klein G. 1977; Establishment in continuous culture of a new type of lymphocyte from a ‘Burkitt like’ malignant lymphoma (line D.G.-75). International Journal of Cancer 19:27–33
    [Google Scholar]
  5. Birkenbach M., Liebowitz D., Wang F., Sample J., Kieff E. 1989; Epstein-Barr virus latent infection membrane protein increases vimentin expression in human B-cell lines. Journal of Virology 63:4079–4084
    [Google Scholar]
  6. Brooks L., Yao Q. Y., Rickinson A. B., Young L. S. 1992; Epstein-Barr virus latent gene transcription in nasopharyngeal carcinoma cells: coexpression of EBNA1, LMP1, and LMP2 transcripts. Journal of Virology 66:2689–2697
    [Google Scholar]
  7. Cuomo L., Trivedi P., Wang F., Winberg G., Klein G., Masucci M. G. 1990; Expression of the Epstein-Barr virus (EBV)-encoded membrane antigen (LMP) increases the stimulatory capacity of EBV-negative B lymphoma lines in allogeneic mixed lymphocyte cultures. European Journal of Immunology 20:2293–2299
    [Google Scholar]
  8. Cuomo L., Ramquist T., Trivedi P., Wang F., Klein G., Masucci M. G. 1992; Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. International Journal of Cancer 51:949–955
    [Google Scholar]
  9. Cuomo L., Trivedi P., de Campos-Lima P. O., Zhang Q. J., Ragnar E., Klein G., Masucci M. G. 1993; Selective induction of allo- stimulatory capacity after 5-azaC treatment of EBV carrying but not EBV negative Burkitt lymphoma cell lines. MolecularImmunology 30:441–450
    [Google Scholar]
  10. Dawson C. W., Rickinson A. B., Young L. S. 1990; Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature 344:777–780
    [Google Scholar]
  11. Fahraeus R., Fu H. L., Ernberg I., Finke J., Rowe M., Klein G., Falk K., Nilsson E., Yadav M., Busson P. others 1988; Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. International Journal of Cancer 42:329–338
    [Google Scholar]
  12. Fahraeus R., Jansson A., Ricksten A., Sjoblom A., Rymo L. 1990a; Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element. Proceedings of the National Academy of Sciences, USA 87:7390–7394
    [Google Scholar]
  13. Fahraeus R., Rymo L., Rhim J. S., Klein G. 1990b; Morphological transformation of human keratinocytes expressing the LMP gene of Epstein-Barr virus. Nature 345:447–449
    [Google Scholar]
  14. Fahraeus R., Chen W., Trivedi P., Klein G., Obrink B. 1992; Decreased expression of E-cadherin and increased invasive capacity in EBV-LMP-transfected human epithelial and murine adenocarcinoma cells. International Journal of Cancer 52:834–838
    [Google Scholar]
  15. Hammarskjold M. L., Simurda M. C. 1992; Epstein-Barr virus latent membrane protein transactivates the human immunodeficiency virus type 1 long terminal repeat through induction of NF-kappa B activity. Journal of Virology 66:6496–6501
    [Google Scholar]
  16. Henderson S., Rowe M., Gregory C., Croom-Carter D., Wang F., Longnecker R., Kieff E., Rickinson A. 1991; Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell 65:1107–1115
    [Google Scholar]
  17. Herrero J. A., Mathew P., Paya C. V. 1995; LMP-1 activates NF- kappa B by targeting the inhibitory molecule I kappa B alpha. Journal of Virology 69:2168–2174
    [Google Scholar]
  18. Hu L. F., Chen F., Zheng X., Ernberg I., Cao S. L., Christensson B., Klein G., Winberg G. 1993; Clonability and tumorigenicity of human epithelial cells expressing the EBV encoded membrane protein LMP1. Oncogene 8:1575–1583
    [Google Scholar]
  19. Jiang W. Q., Szekely L., Wendel-Hansen V., Ringertz N., Klein G., Rosen A. 1991; Co-localization of the retinoblastoma protein and the Epstein-Barr virus-encoded nuclear antigen EBNA-5. Experimental Cell Research 197:314–318
    [Google Scholar]
  20. Kaye K. M., Izumi K. M., Kieff E. 1993; Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proceedings of the National Academy of Sciences, USA 90:9150–9154
    [Google Scholar]
  21. Klein G., Dombos L., Gothoskar B. 1972; Sensitivity of Epstein-Barr virus (EBV) producer and non-producer human lympho- blastoid cell lines to superinfection with EBV. International Journal of Cancer 10:44–57
    [Google Scholar]
  22. Kriauciunas K. M., Goldstein B. J., Lipes M. A., Kahn C. R. 1993; Modulation of expression of insulin and IGF-I receptor by Epstein-Barr virus and its gene products LMP and EBNA-2 in lymphocyte cell lines. Journal of Cellular Physiology 154:486–495
    [Google Scholar]
  23. Kuzumaki N., More I. A., Cochran A. J., Klein G. 1980; Thirteen new mammary tumor cell lines from different mouse strains. European Journal of Cancer 16:1181–1192
    [Google Scholar]
  24. Lenoir G. M., Vuillaume M., Bonnardel C. 1985; The use of lymphomatous and lymphoblastoid cell lines in the study of Burkitt’s lymphoma. IARC Science Publication. 309–318
    [Google Scholar]
  25. Liebowitz D., Kieff E. 1989; Epstein-Barr virus latent membrane protein: induction of B-cell activation antigens and membrane patch formation does not require vimentin. Journal of Virology 63:4051–4054
    [Google Scholar]
  26. Liebowitz D., Wang D., Kieff E. 1986; Orientation and patching of the latent infection membrane protein encoded by Epstein-Barr virus. Journal of Virology 58:233–237
    [Google Scholar]
  27. Liebowitz D., Kopan R., Fuchs E., Sample J., Kieff E. 1987; An Epstein-Barr virus transforming protein associates with vimentin in lymphocytes. Molecular and Cellular Biology 7:2299–2308
    [Google Scholar]
  28. Mosialos G., Birkenbach M., Yalamanchili R., VanArsdale T., Ware C., Kieff E. 1995; The Epstein-Barr virus transforming protein LMP1 engages signaling proteins for the tumor necrosis factor receptor family. Cell 80:389–399
    [Google Scholar]
  29. Nakagomi H., Dolcetti R., Bejarano M. T., Pisa P., Kiessling R., Masucci M. G. 1994; The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. International Journal of Cancer 57:240–244
    [Google Scholar]
  30. Niedobitek G., Fahraeus R., Herbst H., Latza U., Ferszt A., Klein G., Stein H. 1992; The Epstein-Barr virus encoded membrane protein (LMP) induces phenotypic changes in epithelial cells. Virchows Archiv B, Cell Pathology Including Molecular Pathology 62:55–59
    [Google Scholar]
  31. Rowe M., Peng-Pilon M., Huen D. S., Hardy R., Croom-Carter D., Lundgren E., Rickinson A. B. 1994; Upregulation of bcl-2 by the Epstein-Barr virus latent membrane protein LMP1: B-cell-specific response that is delayed relative to NF-kappaB activation and to induction of cell surface markers. Journal of Virology 68:5602–5612
    [Google Scholar]
  32. Rowe M., Khanna R., Jacob C. A., Argaet V., Kelly A., Powis S., Belich M., Croom-Carter D., Lee S., Burrows S. R. others 1995; Restoration of endogenous antigen processing in Burkitt's lymphoma cells by Epstein-Barr virus latent membrane protein-1: coordinate up-regulation of peptide transporters and HLA-class I antigen expression. European Journal of Immunology 25:1374–1384
    [Google Scholar]
  33. Szekely L., Uzvolgyi E., Jiang W. Q., Durko M., Wiman K. G., Klein G., Sumegi J. 1991; Subcellular localization of the retinoblastoma protein. Cell Growth & Differentiation 2:287–295
    [Google Scholar]
  34. Szekely L., Selivanova G., Magnusson K. P., Klein G., Wiman K. G. 1993; EBNA-5, an Epstein-Barr virus-encoded nuclear antigen, binds to the retinoblastoma and p53 proteins. Proceedings of the National Academy of Sciences, USA 90:5455–5459
    [Google Scholar]
  35. Szekely L., Jiang W. -Q., Pokrovskaja K., Wiman K. G., Klein G., Ringertz N. 1995; Reversible nucleolar translocation of Epstein-Barr virus-encoded EBNA-5 and hsp70 proteins after exposure to heat shock or cell density congestion. Journal of General Virology 76:2423–2432
    [Google Scholar]
  36. Szekely L., Pokrovskaja K., Jiang W. Q., Dethe H., Ringertz N., Klein G. 1996; The Epstein-Barr virus-encoded nuclear antigen EBNA-5 accumulates in PML-containing bodies.. Journal of General Virology 70:2562–2568
    [Google Scholar]
  37. Szekely L., Pokrovskaja K., Ringertz N., Klein G. 1997; Differential expression of nucleoskeleton and cytoskeleton associated proteins in Burkitt lymphoma derived and in EBV induced lympho-blastoid cell lines. Cell Growth & Differentiation in press
    [Google Scholar]
  38. Torsteinsdottir S., Andersson M. L., Avila-Carino J., Ehlin-Henriksson B., Masucci M. G., Klein G., Klein E. 1989; Reversion of tumorigenicity and decreased agarose clonability after EBV conversion of an IgH/myc translocation-carrying BL line. International Journal of Cancer 43:273–278
    [Google Scholar]
  39. Trivedi P., Masucci M. G., Winberg G., Klein G. 1991; The Epstein-Barr-virus-encoded membrane protein LMP but not the nuclear antigen EBNA-1 induces rejection of transfected murine mammary carcinoma cells. International Journal of Cancer 48:794–800
    [Google Scholar]
  40. Trivedi P., Hu L. F., Chen F., Christensson B., Masucci M. G., Klein G., Winberg G. 1994; Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue. European Journal of Cancer 30A:84–88
    [Google Scholar]
  41. Wang D., Liebowitz D., Kieff E. 1985; An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43:831–840
    [Google Scholar]
  42. Wang D., Liebowitz D., Kieff E. 1988a; The truncated form of the Epstein-Barr virus latent-infection membrane protein expressed in virus replication does not transform rodent fibroblasts. Journal of Virology 62:2337–2346
    [Google Scholar]
  43. Wang D., Liebowitz D., Wang F., Gregory C., Rickinson A., Larson R., Springer T., Kieff E. 1988b; Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype : deletion of the amino terminus abolishes activity. Journal of Virology 62:4173–4184
    [Google Scholar]
  44. Wang F., Gregory C., Sample C., Rowe M., Liebowitz D., Murray R., Rickinson A., Kieff E. 1990; Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23. Journal of Virology 64:2309–2318
    [Google Scholar]
  45. Wilson J. B., Weinberg W., Johnson R., Yuspa S., Levine A. J. 1990; Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell 61:1315–1327
    [Google Scholar]
  46. Zhang Q., Brooks L., Busson P., Wang F., Charron D., Kieff E., Rickinson A. B., Tursz T. 1994; Epstein-Barr virus (EBV) latent membrane protein 1 increases HLA class II expression in an EBV-negative B cell line. European Journal of Immunology 24:1467–1470
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/0022-1317-78-8-2031
Loading
/content/journal/jgv/10.1099/0022-1317-78-8-2031
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error